LOGIN  |  REGISTER
Amneal Pharmaceuticals

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

November 07, 2025 | Last Trade: US$27.61 1.64 6.31

BOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Event: Guggenheim 2nd Annual Healthcare Innovation Conference
Date: Wednesday, November 12, 2025
Fireside Chat: 10:30 AM ET

Event: Jefferies Global Healthcare Conference in London
Date: Tuesday, November 18, 2025
Fireside Chat: 2:00 PM GMT/ 9:00 AM ET

Event: 37th Annual Piper Sandler Healthcare Conference
Date: Tuesday, December 2, 2025
Fireside Chat: 3:00 PM ET

Event: 8th Annual Evercore Healthcare Conference
Date: Wednesday, December 3, 2025
Fireside Chat: 9:35 AM ET

Event: Oppenheimer Movers in Rare Disease Summit
Date: Thursday, December 11, 2025

Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, and fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. For more information, visit www.centessa.com, which does not form part of this release.

Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page